News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
BioSante Pharmaceuticals, Inc. Reports LibiGel(R) Status and Financial Results for 2008
March 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the status of LibiGel in development for the treatment of female sexual dysfunction and financial results for the year ended December 31, 2008.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
·
3 min read
·
Jennifer Smith-Parker
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
·
2 min read
·
Jennifer Smith-Parker
